Windtree Therapeutics, Inc.
WINTOTCHealthcare● Active
$0.01
$-0.00(-0.69%)
Market Cap$482036
P/E Ratio—
52W High$1.86
52W Low$0.01
Windtree Therapeutics, Inc. (WINT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
WINT · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 19, 2025EPS Actual
-$1.08
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 19, 2025
After Market Close
✓ 2-Quarter EPS Beat Streak
WINT reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 29, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | Apr 8, 2026 | $18.00 | — | — | — | $0.00B | — |
| — Q4 FY2025 | Nov 19, 2025 | — | -$1.08 | — | — | — | — |
| ▲ Q3 FY2025 | Aug 19, 2025 | -$99.00 | -$3.06 | +96.9% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$180.00 | -$4.63 | +97.4% | — | $0.00B | — |
| ▼ Q2 FY2025 | Apr 15, 2025 | -$23.32 | -$99.99 | -328.8% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 26, 2024 | -$2.27 | -$211.50 | -9217.2% | — | — | — |
| ▼ Q3 FY2024 | Aug 19, 2024 | -$405.50 | -$1045.50 | -157.8% | — | — | — |
Q2 FY2026
May 29, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 8, 2026
EPS Actual
—
EPS Est.
$18.00
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 19, 2025
EPS Actual
-$1.08
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 19, 2025Beat
EPS Actual
-$3.06
EPS Est.
-$99.00
EPS Surpr.
+96.9%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$4.63
EPS Est.
-$180.00
EPS Surpr.
+97.4%
Revenue
—
Q2 FY2025
Apr 15, 2025Miss
EPS Actual
-$99.99
EPS Est.
-$23.32
EPS Surpr.
-328.8%
Revenue
$0.00B
Q4 FY2024
Nov 26, 2024Miss
EPS Actual
-$211.50
EPS Est.
-$2.27
EPS Surpr.
-9217.2%
Revenue
—
Q3 FY2024
Aug 19, 2024Miss
EPS Actual
-$1045.50
EPS Est.
-$405.50
EPS Surpr.
-157.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $18.00 | $18.00 | $18.00 | 1 |
| Q3 FY2025 | $-54.00 | $-54.00 | $-54.00 | 1 |
| Q2 FY2025 | $-99.00 | $-99.00 | $-99.00 | 1 |
| Q1 FY2025 | $-180.00 | $-180.00 | $-180.00 | 1 |
| Q4 FY2024 | $-39.00 | $-39.00 | $-39.00 | 1 |
| Q3 FY2024 | $-113.50 | $-113.50 | $-113.50 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2025 | Nov 19, 2025 | — | $0.06 | $0.05 | -16.67% |
| ▲ Q3 FY2025 | Aug 19, 2025 | +96.9% | $0.49 | $0.48 | -2.04% |
| ▲ Q2 FY2025 | May 15, 2025 | +97.4% | $0.87 | $0.83 | -4.60% |
| ▼ Q2 FY2025 | Apr 15, 2025 | -328.8% | $1.36 | $1.18 | -13.24% |
| ▼ Q4 FY2024 | Nov 26, 2024 | -9217.2% | $27.83 | $28.18 | +1.26% |
| ▼ Q3 FY2024 | Aug 19, 2024 | -157.8% | $590.00 | $550.00 | -6.78% |
| ▲ Q2 FY2024 | May 15, 2024 | +6.6% | $203.00 | $230.00 | +13.30% |
| ▼ Q2 FY2024 | Apr 16, 2024 | -70694.7% | $382.00 | $379.50 | -0.65% |
Q4 FY2025-16.67%
Report Date
Nov 19, 2025
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.05
Q3 FY2025-2.04%
Report Date
Aug 19, 2025
EPS Beat/Miss
+96.9%
Price Before
$0.49
Price After
$0.48
Q2 FY2025-4.60%
Report Date
May 15, 2025
EPS Beat/Miss
+97.4%
Price Before
$0.87
Price After
$0.83
Q2 FY2025-13.24%
Report Date
Apr 15, 2025
EPS Beat/Miss
-328.8%
Price Before
$1.36
Price After
$1.18
Q4 FY2024+1.26%
Report Date
Nov 26, 2024
EPS Beat/Miss
-9217.2%
Price Before
$27.83
Price After
$28.18
Q3 FY2024-6.78%
Report Date
Aug 19, 2024
EPS Beat/Miss
-157.8%
Price Before
$590.00
Price After
$550.00
Q2 FY2024+13.30%
Report Date
May 15, 2024
EPS Beat/Miss
+6.6%
Price Before
$203.00
Price After
$230.00
Q2 FY2024-0.65%
Report Date
Apr 16, 2024
EPS Beat/Miss
-70694.7%
Price Before
$382.00
Price After
$379.50
Avg Beat Reaction+2.22%
Avg Miss Reaction-4.85%
Beat Rate3 / 8 quarters
Largest Move-16.67% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: WINT ends December
Windtree Therapeutics, Inc. (WINT) most recently reported earnings on November 19, 2025 for Q4 FY2025, posting EPS of $-1.08 (in line with the analyst consensus of —). WINT has beaten EPS estimates for 2 consecutive quarters. The next WINT earnings date is expected around September 1, 2026.
Each quarter, investors track WINT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. WINT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
WINT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
WINT earnings · 4 questionsWindtree Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. WINT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; WINT historically reports after market close (AMC).
WINT earnings datewhen is WINT earningsWINT next earnings datewhen does WINT report earningsWINT earnings calendar
▸ Source: FMP · Windtree Therapeutics, Inc. SEC filings · US GAAP · Windtree Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026